Equities

Rua Life Sciences PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AOHA:FRA

Rua Life Sciences PLC

Actions
  • Price (EUR)0.124
  • Today's Change0.00 / 0.00%
  • Shares traded13.18k
  • 1 Year change+5.08%
  • Beta0.0344
Data delayed at least 15 minutes, as of Feb 12 2026 20:50 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

RUA Life Sciences plc is a United Kingdom-based holding company of a group of medical device businesses focused on the exploitation of long-term implantable biostable polymer (Elast-Eon). Elast-Eon's biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. The Company has four business units: RUA Contract Manufacture, RUA Biomaterials, RUA Vascular and RUA Structural Heart. RUA Contract Manufacture is an end-to-end contract developer and manufacturer of medical devices and implantable fabric specialists. It provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class 7 and 8 cleanroom suites. RUA Biomaterials is a licensor of Elast-Eon polymers to the medical device industry. RUA Vascular is engaged in the commercialization of open surgical vascular grafts and patches. RUA Structural Heart is engaged in the development of polymeric leaflet systems for heart valves.

  • Revenue in GBP (TTM)5.17m
  • Net income in GBP-850.00k
  • Incorporated1996
  • Employees33.00
  • Location
    Rua Life Sciences PLC2 Drummond Crescent, IrvineAYRSHIRE KA11 5ANUnited KingdomGBR
  • Phone+44 129 431 7073
  • Fax+44 193 225 1113
  • Websitehttps://rualifesciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.